Favipiravir, a novel nucleoside analogue, can clear a persistent norovirus infection in vivo through lethal mutagenesis.

Once an influenza infection is established, selection acts efficiently in favouring fitter viral genotypes, its effects being limited only by the short length of a typical infection.

Immune markers measured at the early stage of COVID-19 infection are associated with various clinical outcomes and can be used to predict disease progression, T cell memory, viral shedding, and the antibody response of the COVID-19 patients.

Pharmacometric evaluation of viral clearance rates based on frequent oropharyngeal sampling is a highly efficient and well-tolerated method of assessing and comparing SARS-CoV-2 antiviral therapeutics in vivo.

NICEdrug.ch is a resource allowing systematic and large-scale computational analysis of drug biochemistry, enzymatic targets, and toxicity in the context of cellular metabolism.

High-throughput and ultra-stable magnetic tweezers reveal that Remdesivir induces a long-lived backtrack pause upon incorporation by the coronavirus polymerase, and SARS-CoV-2 is able to evade interferon-induced antiviral ddhCTP.

A new assay for specific mutational classes provides preciseestimates of the mutation rates and mutational bias for influenza A viruses.

The anti-HIV drug lenacapavir breaks the HIV capsid by stabilising regions of low curvature at the expense of maintaining a closed shell, leading to loss of viral DNA synthesis and inhibition of infection.